Logo

People in the News: Michael Templin

Jun 27, 2013
Premium

SNBL USA, a contract research organization, has named Michael Templin as field technical director.

In the role, Templin will work with the company’s business development and internal scientific teams to provide clients with scientific and regulatory guidance for preclinical drug-development programs.

Prior to joining SNBL, Templin served as chief technology officer at Marina Biotech.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
Marina
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.